Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters00:54

Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters

The noncompartmental approach is a widely used method in pharmacokinetics to assess drugs' behaviors in the body. It considers several factors, including clearance, bioavailability, and total volume of distribution.
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's overall...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of allogeneic umbilical cord blood mononuclear cells therapy in children with autism spectrum disorder and immune dysregulation: a single-center, double-blinded, randomized, placebo-controlled trial.

Stem cell research & therapy·2026
Same author

Quality and consistency of genetic newborn screening reports in China: insights from a multi-laboratory analysis using simulated samples.

BMC pediatrics·2026
Same author

Causal Directed Acyclic Graphs to Mitigate Confounding Bias in Exposure-Response Analyses.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Latent Variable Indirect Response Modeling of Cendakimab Exposure-Response for Longitudinal Dysphagia Days Using a Combined Uniform-Binomial Likelihood Framework.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Integrating MBMA and QSP to Identify Key Covariates and Predict Treatment Outcomes in Relapsed/Refractory Multiple Myeloma.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Reliable LC-MS/MS method development and validation for the determination of methylmalonic acid, methylcitric acid, malonic acid, ethylmalonic acid, and total homocysteine in dried blood spots.

Clinical biochemistry·2025

Related Experiment Video

Updated: Jun 17, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Confirmatory analysis for phase III population pharmacokinetics.

Chuanpu Hu1, Ji Zhang, Honghui Zhou

  • 1Pharmacokinetics, Modeling & Simulation, Centocor R&D, Inc., Malvern, PA 19355, USA. CHu25@its.jnj.com

Pharmaceutical Statistics
|December 31, 2009
PubMed
Summary

A confirmatory statistical approach for population pharmacokinetics (POPPK) analysis significantly reduces drug development time. This method provides more accurate and interpretable results for dose adjustments and labeling compared to traditional exploratory methods.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Related Experiment Videos

Last Updated: Jun 17, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Area of Science:

  • Pharmacometrics
  • Clinical Pharmacology
  • Biostatistics

Background:

  • Population pharmacokinetics (POPPK) analysis is crucial for drug development, aiding dose adjustment and labeling.
  • Current nonlinear mixed-effect modeling approaches are often time-consuming due to extensive model exploration.

Purpose of the Study:

  • To propose and evaluate a confirmatory statistical analysis approach for POPPK.
  • To demonstrate the efficiency and accuracy of this approach compared to traditional exploratory methods.

Main Methods:

  • Utilized a confirmatory statistical approach with prespecified primary and sensitivity analyses.
  • Applied the method to a Phase III clinical study dataset.
  • Compared results with those from a common exploratory nonlinear mixed-effect modeling approach.

Main Results:

  • The confirmatory approach substantially reduced analysis time.
  • This method yielded more accurate and interpretable pharmacokinetic results.
  • Identified covariate influences for potential dose adjustments and labeling.

Conclusions:

  • A confirmatory statistical analysis framework offers a more efficient and effective strategy for POPPK studies.
  • This approach can improve the accuracy and interpretability of findings in drug development.
  • The methodology shows potential for application in earlier clinical trial phases (Phase I and II).